Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Paige Biopharmaceutical-B (02565.HK) Innovative Candidate CR059 Selected as ADA Latest Breaking Abstract
Recommend 2 Positive 1 Negative 1 |
||||
|
||||
|
Paige Biopharmaceutical-B (02565.HK) announced that a research abstract related to its self-developed innovative candidate CR059 has been accepted by the American Diabetes Association (ADA) for presentation at the ADA 2026 Scientific Sessions and has been selected as a latest breaking abstract. The study will be presented in poster format. According to the research results, CR059 demonstrated significant weight-loss effects, outstanding glucose-lowering performance and long-term expression characteristics, indicating its development potential as a long-acting therapeutic solution for metabolic diseases. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
